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Animal models that closely mimic the human condition are of paramount significance to study pathogenic mechanisms, vaccine and therapy
scenarios. This is particularly true for investigations that involve emerging infectious diseases. Nonhuman primate species represent an
alternative to the more intensively investigated rodent animal models and in a number of instances have been shown to represent a more
reliable predictor of the human response to infection. West Nile virus (WNV) has emerged as a new pathogen in the Americas. It has a 5%
fatality rate, predominantly in the elderly and immune compromised. Typically, infections are cleared by neutralizing antibodies, which
suggests that a vaccine would be efficacious. Previously, only macaques had been evaluated as a primate model for WNV vaccine design. The
macaques did not develop WNV disease nor express the full complement of IgG subclasses that is found in humans. We therefore explored
baboons, which exhibit the similar four IgG subclasses observed in humans as a new model for WNV infection and vaccine evaluation. In this
present report, we describe the experimental infection of baboons with WNV and test the efficacy of an inactivated WNV vaccination strategy.
All experimentally infected animals developed transient viremia and subsequent neutralizing antibodies. Anti-WNV IgM antibodies peaked at
20 days post-infection. Anti-WNV IgG antibodies appeared later and persisted past 60 days. Prior vaccination with chemically inactivated virus
induced neutralizing titers and a fast, high titer IgG recall response, which resulted in lower viremia upon challenge. This report is the first to
describe the development of the baboon model for WNV experimental infection and the utility of this model to characterize the immunologic
response against WNV and a candidate WNV vaccine.
© 2006 Elsevier Inc. All rights reserved.Keywords: West Nile virus; Vaccine; BaboonIntroduction
Fever, peripheral viremia and an ensuing IgM, IgG and
neutralizing antibody response characterize WNV infection in
humans (Hayes et al., 2005a, 2005b; Lanciotti et al., 1999).
Since no WNV-specific anti-viral drugs are available, patients
can only be treated with palliative therapy (e.g. intravenous
fluids). Still, most hospitalized patients recover and ultimately
clear viral infection due to the inherent ability in even an⁎ Corresponding author. Department of Microbiology and Immunology and
Lineberger Comprehensive Cancer Center, University of North Carolina at
Chapel Hill, CB# 7290, 804 Mary Ellen Jones Bldg, Chapel Hill, NC 27599-
7290, USA. Fax: +1 919 962 8103.
E-mail address: ddittmer@med.unc.edu (D.P. Dittmer).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.06.033immunologically naive host to mount a timely immune
response and to control WNV infection. Upon natural exposure
of humans, WNV clearance is found most often, WNV-
associated clinical disease is seen as an exception. If the
immune system fails, however, uncontrolled WNV spreads to
the central nervous system and causes death by flaccid
paralysis. The most severe disease phenotypes are observed
after WNV infection of immune compromised individuals, such
as after blood transfusion or organ transplantation (Iwamoto et
al., 2003; Pealer et al., 2003). During WNVepidemics, as many
as 1 in 150 blood donations can have detectable levels of
viremia. During the 2002–2003 WNV epidemic in the United
States, all cases of transfusion–transmission resulted from
WNV IgM-negative donations (Busch et al., 2005; Petersen and
Epstein, 2005; Stramer et al., 2005), which is consistent with the
45R.F. Wolf et al. / Virology 355 (2006) 44–51ability of IgM and/or IgG to prevent transmission. Hence, there
exists a continued need to develop WNV vaccines and the hope,
based on natural transmission data, that they would be
efficacious. The murine model of WNV infection has been the
most intensively investigated and is presently the preferred
animal model for WNV research. The mouse model has allowed
investigators to gain valuable information with regard to the
immune response to WNV infection. Mice are susceptible to
WNV infection, with LD50s as low as 1 pfu after peripheral
injection (i.p., i.v. or foodpad) (Beasley et al., 2002; Papin et al.,
2005). The small size of mice and their high susceptibility offer
enormous practical benefits but may yield overly pessimistic
results in vaccine studies compared to the much less susceptible
primates (including humans). Susceptibility to infection in mice
has been mapped to 2′–5′-oligoadenylate synthetase (OAS)
(Mashimo et al., 2002; Perelygin et al., 2002). OAS limits WNV
replication cell autonomously, even after intracranial (i.c.)
injection, which bypasses the normal innate and adaptive
immune responses. Studies in B-cell-deficient mice showed that
neutralizing antibodies limit systemic spread and mortality
(Diamond et al., 2003a, 2003b). Much has been learned about
the antibody response to WNV using murine challenge models,
in which prior immunization and post-exposure IgG treatment
protects against disease. This body of work implicates the
humoral immune response and neutralizing antibodies as
correlates of protective immunity in WNV infection (Engle
and Diamond, 2003; Oliphant et al., 2005; Tesh et al., 2002;
Gould et al., 2005).
There are drawbacks to the mouse model of WNV
infection and its use to assess the induction of immune
responses and vaccine efficacy when testing new approaches.
An example is that the mouse immune system and how it
responds to WNV infection differs from the human immune
response to this organism and other viral infections (Mestas
and Hughes, 2004). Additionally, not all disease manifesta-
tions observed in humans were also observed in mice
following WNV infection. As an alternative to mice, macaque
species have been the nonhuman primate model of choice to
study viral infections and provide the closest animal model to
study the immune response to infection and vaccination.
However, this model also has its limitations for investigations
involving WNV. Macaques often carry the herpes B virus,
which can be fatal to animal handlers that become
inadvertently exposed to infected animals or tissues. More
important to vaccine design, macaques lack the opsonizing
antibody subclass IgG3, which in general reacts against
protein antigens and readily activates complement (Kennedy
et al., 1997). Recently, macaques, particularly rhesus mon-
keys, have been difficult to obtain and have become expensive
due to their limited supply and use as the preferred nonhuman
primate model for AIDS research. In contrast, the baboon
(Papio species), another nonhuman primate model, are widely
available and cost efficient mainly because they breed well in
captivity. Unlike macaques, baboons do not harbor herpes B
virus and have four IgG subclasses analogous to humans,
which allows for more thorough investigation of vaccine
aimed at inducing a protective antibody response. Hence,baboons have been utilized as animal models in the infectious
disease arena and to test the safety and immunogenicity of
human candidate vaccines. This includes bacterial, protozoal
and viral infections, such as group A and B Streptococcus,
group B meningococcus, Haemophilus influenzae type b,
Schistosoma mansoni, Trypanosoma cruzi, human immuno-
deficiency virus, human T cell leukemia virus, hepatitis B
virus, Epstein–Barr virus and rotavirus, among others (for
example, Bot et al., 2001; Jenson et al., 2000; Kalina et al.,
2005; Kariuki et al., 2004; Kennedy et al., 1997; Payton et al.,
2004; Siddiqui et al., 2005; Watts et al., 1999; Wolf et al.,
2006). Thus, the aims of this study were to determine (a)
whether we could develop an experimental infection with
WNV in baboons and (b) whether this experimental infection
model could be used to assess the immune response and
efficacy of a prototypic WNV vaccine.
Results
WNV infection in baboons
We infected three baboons (Papio hamardryas anubis) with
105 pfu of WNV OK02 in 0.1 ml PBS by intradermal injection.
OK02, like NY99 (Beasley et al., 2002), is neuroinvasive and
causes 100% mortality in mice (Papin et al., 2005). The animals
were monitored daily and blood drawn prior to infection and at
daily intervals up to day 14 and thereafter at days 21, 28, 42 and
56. Viral RNA was isolated from serum using QiAmp Viral
RNA (Quiagen Inc.) according to manufacturer's recommenda-
tions. We used our previously developed quantitative real-time
PCR assay to determine viral load (Papin et al., 2004b). WNV
replicated in each animal with peak serum titers of 105–106
copies/ml at day 4 post-infection (Fig. 1). By day 10, virus was
no longer detectable in serum. This kinetic pattern is similar to
human infection (Hayes et al., 2005a). One animal developed a
transient macular rash but showed no other clinical signs that
might typify more severe disease such as weakness, disorienta-
tion or flaccid paralysis. This is not surprising since, in human
infection as well, the ratio of clinically unapparent to apparent
infections is estimated at 140–320:1 (Richman et al., 2002).
Hence, the baboon infection model mimics the clinical course of
primary human infection by WNV.
The antibody response to WNV in the three baboons
followed the prototypical pattern of WNV infections in
healthy human adults (Fig. 2). We were able to use a
commercial WNV ELISA (Focus Diagnostics, Inc., Herndon,
VI) since anti-IgG and anti-IgM antisera recognized baboon
heavy chains as well as human heavy chains. This test is used
to detect WNV in patients, and WNV reactivity is expressed
as index value relative to positive and negative control. An
index value >1 is considered positive. The response across
the three experimental animals was remarkably homogenous.
Anti-WNV-specific IgM antibodies peaked at approximately
20 days post-infection and then decreased to within two-fold
above normal at day 57. Anti-WNV-specific IgG antibody
levels increased up to day 25 and then more slowly until day
57, the end of the observation period. Next, we determined
Fig. 2. Individual, (A) IgM and (B) IgG response to WNV in n=3 baboons. (C)
Mean and SD of IgM and IgG responses. Index >1 indicates the presence of
WNV antibodies.
Fig. 1. Peripheral viremia in WNV-infected baboons (A) without immunization
and (B) after immunization with killed virus vaccine.
Table 1
Geometric mean neutralizing titer
Animal Sex Age/Years p.i. a Day 11 21 days
#795 f 9 1855 3363 nd b
#1201 m 3 736 5750 c nd
#69–362 f 5.5 d 464 5750 nd
#7228 f 16.5 292 5750 nd
#1196 f 7.5 736 5750 nd
#298 m 7 na e nd 1250
#561 m 7.5 na nd 731
#565 m 8d na nd 146
a Post-immunization (three weeks after last boost).
b Not determined.
c Maximal dilution.
d Estimated; wild-caught animal.
e Not applicable.
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1). At day 21 p.i., the geometric mean neutralizing titers were
1:1250, 1:731 and 1:146. This establishes that the immune
response to WNV in the baboon is similar to the human
response to WNV exposure.
IgG, IgM and neutralizing antibodies are induced by a
chemically inactivated WNV vaccine
To evaluate a killed WNV vaccine (West Nile-Innovator,
Ft. Dodge Animal Health Inc., Ft. Dodge, IO) in baboons, we
vaccinated five animals i.m. and boosted twice at 2-week
intervals using the manufacturer's recommended dose
(approximately 107 TCID50). Three weeks after the last
boost, the animals were infected with 105 pfu WNV-OK02
i.d. WNV-specific IgG and IgM titers were determined by
ELISA. With the exception of animal 795, there were no pre-
immunization (PI) IgM or IgG antibodies to WNV (Fig. 3B).
After immunization and prior to challenge (PCS), each animal
developed significant WNV-specific IgG antibodies (Fig. 3B,
compare group PCS to PI, p≤0.001 by Student's t test,
n=5). The IgG levels induced by the killed virus vaccine after
two boosts were as high as IgG levels at 21 days after
challenge of the same animals with live virus (Fig. 3B,
compare group d21 to PCS) and significantly higher than the
positive control (PC). This suggests that chemically inacti-
vated WNV was as efficient as natural infection in inducing
IgG antibodies.
We did not detect IgM antibodies prior to immunization (PI)
except for animal #795 (Fig. 3A). The IgM levels for all animals
including #795 were barely above the cut-off value, but not
significantly so at 3 weeks after the last boost (PCS) (Fig. 3Acompare group PI to PCS). This was expected since we wanted
the IgM levels, i.e. the primary response, to decline prior to
challenge such that we could measure the vaccine-primed
secondary response. In contrast to naive animals (298, 561,
Fig. 3. (A) Outline of the vaccination regimen. (B) IgM response to WNV immunization. (C) IgM response to WNV immunization. PC, NC positive, negative control
from Focus Inc. ELISA. Mouse control serum from IM or IP challenge. PI, pre-immunization with fixed WNV vaccine, PCS, pre-challenge, d21 and d14, days 14 and
21 post-challenge with WNV. Index >1 indicates the presence of WNV antibodies. Numbers indicate individual animals.
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day 21 after WNV infection (Fig. 3A group naive compare PI to
d14 and d21, p≤0.05 by Student's t test), the immunized
animals (795, 1201, 69–326, 1196, 7228) did not develop IgM
antibodies after WNV infection. Rather, they developed IgG
antibodies. Class switching from IgM to IgG due to vaccination
at day 21 was significant to p≤0.008 when comparing
vaccinated (n=5) to naive animals (n=3) (Fig. 3A compare
d21 for animals 795, 1201, 69–326, 1196 and 7228 to naive
animals 298, 561 and 565). This demonstrated that our prime/boost regimen induced a WNV-specific, IgG-dominated B cell
memory response.
Next, we determined WNV plaque reduction neutralizing
titers (PRNT). For PRNT, virus was mixed with antiserum at 5-
fold dilutions and incubated at room temperature for 60 min
prior to plaque assay on Vero cells (Beasley and Barrett, 2002).
PRNT were induced by killed WNV vaccine prior to challenge
(1:816, n=5) similar to live virus infection (1:709, n=3), but
challenge of immunized animals induced even higher titers
(1:5272, n=5) at day 11 after WNV infection (Table 1). This is
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PRNT titers observed in infected, naive animals, it suggests that
even if PRNT titers are not dramatic after vaccination, the host
can mount an accelerated recall response to subsequent
exposure. We also evaluated peripheral viremia (Fig. 1B) and
found it reduced in peak level (5×104 at day 6) in 4/5 animals
and in duration in 5/5 animals relative to naive WNV-infected
baboons. This establishes that killed WNV vaccine induced a
protective immune response in baboons.
Discussion
We developed baboons as a novel nonhuman primate
model for WNV. Studying WNV infection in nonhuman
primates offers unique insights into flavivirus biology and is a
prerequisite step for vaccine evaluation in clinical trials
(Arroyo et al., 2004; Olberg et al., 2004; Ratterree et al.,
2004). Mice represent a wonderful model to uncover the
principal components of host–pathogen interactions, but
exclusive use of murine models runs the risk of overlooking
key aspects of human (primate) immunology (Mestas and
Hughes, 2004). For instance, mice lack the IgA-specific
FcalphaR1 receptor and presumably use CD71, which binds
IgM as well as IgA. Mice also lack homologs to the human
FcGammaRIIA and IIC. Even though we do not know how
these differences may affect the validity of WNV studies in
mice, it is prudent to assume that species differences in
immune modulation can lead to susceptibility differences to
human pathogens and to vaccine efficacy. Furthermore,
primate blood is neutrophil-rich whereas mouse blood is not
(50–70% compared to 10–25% of total white cell count,
respectively). This may provide a much greater reservoir of
innate effector cells, which in primates may contain WNV
until the humoral response develops. Hence, limited systemic
viremia and high-grade fever rather than death (as in mice)
are the normal outcomes of flavivirus infection in macaques,
baboons and humans.
Our studies are significant because they are the first to
describe the controlled experimental infection of baboons
with WNV. WNV-antibody-mediated responses are key to
limiting flavivirus infection (Ben-Nathan et al., 2003;
Diamond et al., 2003a, 2003b; Engle and Diamond, 2003),
and primate-specific properties, such as isotype and repertoire
preferences of the antibody response, need to be considered
for WNV vaccine design and evaluation. The establishment
and maintenance of WNV infection in baboons then allowed
us to evaluate the immune response and efficacy of a
prototypic human vaccine candidate. Other primate species,
such as macaques, can be used to study WNV infection and
yield a similar phenotype upon infection (Arroyo et al., 2004;
Goverdhan et al., 1992; Olberg et al., 2004; Pletnev et al.,
2003; Pogodina et al., 1983; Ratterree et al., 2003, 2004).
However, the biomedical community is experiencing an acute
shortage of macaques (Health, 2003), as wild macaques can
no longer be imported or used, macaques breed in captivity
only seasonally, and most Rhesus macaques born in captivity
are slated for HIV vaccine research. This leaves a significantgap as studies on flavivirus vaccines have progressed rapidly
and need to move from the murine to primate models. The
baboon is underutilized for infectious disease research and
offers an alternative to macaque studies. Baboons have been
used since the 1950 for the purpose of transplantation
research including baboon-to-human and pig-to-baboon xeno-
transplants (Baker, 1995; Kalina et al., 2005; Michaels et al.,
2004; Platt, 2001; Starzl et al., 1993), breed easily in captivity
year round and have a cost advantage over macaques. With
regard to vaccine evaluation against flaviviruses, baboons
provide a unique advantage, namely the presence of multiple
IgG isotypes, which are missing in macaques (Shearer et al.,
1999). Here, we built upon our prior work on baboon models
of viral infections (Kalina et al., 2005; Whitby et al., 2003)
and the accumulated knowledge about baboon physiology,
virology and immunology (Hainsey et al., 1993; Kennedy et
al., 1997; Whitby et al., 2003) to establish a novel nonhuman
primate model for WNV infection and flavivirus vaccine
evaluation.
WNV infection of three baboons yielded uniform peripheral
viremia and humoral immune responses that were virtually
identical to those found in healthy humans exposed to WNV.
During WNV infection of humans, WNV RNA can be detected
between day 2 and 12 post-mosquito bite, IgM and IgG develop
at days 11 and 12, respectively. During WNV infection of
baboons, we detected WNV RNA between day 2 and 6 post-
inoculation and IgM and IgG were first detectable at days 10
and 12, respectively. A chemically inactivated WNV vaccine
reduced peripheral viremia and induced high titer neutralizing
antibodies. Immunized animals developed a faster, IgG-
dominated antibody response than naive animals. This suggests
that vaccination with chemically inactivated virus accelerates
the WNV-specific adaptive immune response and will offer
clinical benefits.Materials and methods
Virus strains
We used two plaque-purified low passage (≤5 passages on
Vero cells) strains (OK02 and OK03) isolated from blue jay
brains during the 2002 and 2003 epidemics (Papin et al.,
2004b). Both strains have been sequenced to confirm their
identity (Papin and Dittmer, unpublished) and belong to US
lineage I (Davis et al., 2005). OK02 and OK03, like NY99
(Beasley et al., 2002), are neuroinvasive and cause 100%
mortality in mice after peripheral administration of ≤103 pfu
per animal (Floyd et al., 2004; Papin et al., 2005).
Plaque assay and plaque reduction neutralization titer (PRNT)
WNV was titered on Vero cells by plaque assay according
to standard procedures (Beasley and Barrett, 2002). For
PRNT, virus was mixed with antiserum at 5-fold dilutions and
incubated at room temperature for 60 min prior to plaque
assay.
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We used our previously developed quantitative real-time
PCR assay for WNV (Papin et al., 2004a). This assay uses
SYBR green as the method of detection and is as sensitive and
as specific as TaqMan-based real-time QPCR assays. Viral
RNA was isolated from serum using QiAmp Viral RNA
(Quiagen Inc.) according to manufacturer's recommendations,
reverse-transcribed and real-time QPCR conducted as described
(Hilscher et al., 20005; Papin et al., 2004a, 2004b).
ELISA
We used a commercial WNV ELISA (Focus Technologies
Inc.) following the manufacturer's protocol. The Focus Inc.
IgM ELISA is a sandwich ELISA using rabbit anti-human
IgM-coated wells to capture all IgM in serum and WNV
antigen and a specific anti-WNV-horseradish-peroxidase
(HRP)-conjugated secondary mouse antibody to recognize
the complex. We were able to utilize this ELISA since the
anti-IgM antiserum recognizes baboon heavy chains as well as
human heavy chains. The Focus Inc. IgG ELISA uses WNV-
antigen-coated wells and anti-IgG/HRP-conjugated detection.
We were able to utilize this ELISA since the anti-IgG
antiserum recognizes baboon as well as human IgG. WNV
reactivity is expressed as index value relative to a positive and
negative control. For IgG, baboon serum, Cut-off Calibrator or
controls were added to antigen-coated polystyrene microwells.
After incubation, peroxidase-conjugated goat antihuman IgG
was added followed by tetramethylbenzidine and hydrogen
peroxide substrate reagent and then stop solution. For IgM,
baboon serum, Cut-off Calibrator or controls were added to
rabbit anti-human IgM-coated polystyrene wells. Following
incubation, recombinant West Nile virus antigen was added
followed by peroxidase-conjugated mouse monoclonal anti-
flavivirus, tetramethylbenzidine and hydrogen peroxide sub-
strate reagent and then stop solution. Wells were read at a
wavelength of 450 nM. Results are reported as index values
relative to the Cut-off Calibrator. An index value >1 is
considered positive.
Animals
Eight baboons (P. hamadryas anubis) of both sexes and
various ages (Table 1) were single-housed in aluminum cages at
the University of Oklahoma Health Sciences Center (OUHSC)
Department of Comparative Medicine's animal facility which is
accredited by the Association for Assessment and Accreditation
of Laboratory Animal Care International. All procedures were
approved by the OUHSC Institutional Animal Care and Use
Committee and are in accordance with the Guide for the Care
and Use of Laboratory Animals and National Research Council
guidelines (Council, 1996). Baboons were fed monkey chow
twice daily and given fruit, popcorn, peanuts and other treats
once a day. For infection, baboons were sedated with an
intramuscular injection of ketamine hydrochloride (approxi-
mately 10 mg/kg). Blood was collected from sedated animalsusing a 20-gauge needle and a 10 ml syringe. Samples were
collected prior to each vaccination, prior to inoculation (day 0)
and on days 1–14, 21, 28, 42 and 56. Blood was divided into a
serum separator tube and a heparin tube and then placed on ice
until it was centrifuged. After clotting for about 2 h, the samples
were centrifuged for 15 min at high speed. The serum or plasma
was decanted and stored at −80 °C. For vaccination, 5 baboons
were injected intramuscularly with killed West Nile Virus
Vaccine (West Nile—Innovator, Fort Dodge Animal Health,
Fort Dodge, Iowa) labeled for horses. Three vaccinations were
given at 2-week intervals. For virus inoculation, a small spot
was shaved in the middle of the back. The area was cleaned with
betadine scrub and then sprayed with alcohol. West Nile virus
(OK03) 105 pfu in a volume of 0.1 ml was injected
intradermally.
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